IP Library Granted Patent US 11,827,621
Granted Patent B2
US 11,827,621 · App. 17/314,777 · Granted Nov 28, 2023

Inhibitors of (α-v)(β-6) integrin

Inventors: Mark Brewer (Wallingford, GB); Matthew G. Bursavich (Needham, MA); Aleksey I. Gerasyuto (Flemington, NJ); Kristopher N. Hahn (Medford, MA); Bryce A. Harrison (Framingham, MA); Kyle D. Konze (Brooklyn, NY); Fu-Yang Lin (Sudbury, MA); Blaise S. Lippa (Newton, MA); Alexey A. Lugovskoy (Belmont, MA); Bruce N. Rogers (Belmont, MA); Mats A. Svensson (New York, NY); Dawn M. Troast (Bedford, MA)
Assignee: Morphic Therapeutic, Inc.
C07D401/12C07D471/04C07D471/08C07D487/08C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,827,621
App. No.
17/314,777
Granted
Nov 28, 2023
Kind
B2
Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Claims (19)

1. A compound of formula (I):

A-B-C  (I)

wherein:

A is

B is -alkylene-C(O)N(R)—, wherein the alkylene is propylene or butylene;

C is

R 2 is H, alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cycloalkyl, -alkylene-alkoxy, alkylene-aryl, or heterocycloalkyl;

R 3 , is H, halide, methyl or OMe;

R is H or methyl; and

each R 1 is independently H, alkyl, halide, alkoxy, CF 3 , OH, alkylene-OH, NO 2 , —N(H)R, or NH 2 , provided at least one instance of R 1 is Me, halide, OMe, OH, alkylene-OH, or NH 2 ;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 3 is H.

3. The compound of claim 1 , wherein at least one instance of R 1 is alkyl, or halide.

4. The compound of claim 1 , wherein R 2 is H.

5. The compound of claim 1 , wherein R 2 is (C 1 -C 4 )alkyl, cyclopropyl, CH 2 OMe, phenyl, —CH 2 Ph, pyridinyl, or indolyl.

6. The compound of claim 5 , wherein R 2 is Me.

7. The compound of claim 5 , wherein R 2 is phenyl or pyridinyl.

8. The compound of claim 7 , wherein the phenyl at R 2 is substituted with one or more independent instances of alkoxy, OH, halide, —N(H)C(O)alkyl, —C(O)NH 2 , or —C(O)alkyl; and wherein the pyridinyl at R 2 is substituted with NH 2 , or OH.

9. The compound of claim 5 , wherein R 2 is

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: BURSAVICH, MATTHEW G.; HAHN, KRISTOPHER N.; HARRISON, BRYCE A.; LIN, FU-YANG; LIPPA, BLAISE S.; LUGOVSKOY, ALEXEY A.; ROGERS, BRUCE N.; TROAST, DAWN M.
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 057035/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: MORPHIC THERAPEUTIC, INC.
To: LAZULI, INC.
Reel/Frame 057035/0409 →
MERGER Recorded Jul 30, 2021
From: LAZULI, INC.
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 057035/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, LLC
Reel/Frame 057046/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: BREWER, MARK; GERASYUTO, ALEKSEY I.; KONZE, KYLE D.; SVENSSON, MATS A.
To: SCHRÖDINGER, INC.
Reel/Frame 057046/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: SCHRÖDINGER, LLC
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 057046/0353 →
Continuity (3)
Continuation 16489628
Provisional Application 62464693 · Feb 28, 2017
Related Publication 20210276975A1 · Sep 9, 2021
Cited By (4)
US 12,415,796 US 12,459,942 US 12,528,803 US 12,552,786